the prolonged period of PD-L1 blockade dramatically enhanced the therapeutic efficacy of PLK1122DC_TriVax, in which complete tumour regressions were attained (two out of eight mice; Fig. S5A, B). The gene discussed is CD274; the disease is neoplasm.